{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:08:55Z","timestamp":1791493735885,"version":"4.3.4"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ymgme.2022.10.005","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T22:19:56Z","timestamp":1667081996000},"page":"328-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues"],"prefix":"10.1016","volume":"137","author":[{"given":"Camilla","family":"T\u00f8ndel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Thurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pronabesh","family":"DasMahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Maski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2022.10.005_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","article-title":"Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry","volume":"163","author":"Scott","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0030","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>a (IVS4+919G>a)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0040","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0045","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","article-title":"Anderson-Fabry disease: a multiorgan disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0050","first-page":"37","article-title":"Paediatric Fabry disease","volume":"5","author":"Ellaway","year":"2016","journal-title":"Transl Pediatr"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0060","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.2174\/13816128113199990387","article-title":"Neurological complications of Anderson-Fabry disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0070","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0075","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1590\/S1415-47572012000600009","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis","volume":"35","author":"Alegra","year":"2012","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0080","series-title":"EMA, Summary of Product Characteristics (Replagal)","year":"2008"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0085","series-title":"EMA, Summary of product characteristics (Fabrazyme)","year":"2001"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0090","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two \u03b1-galactosidase a orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0095","series-title":"Sanofi, Highlights of prescribing Information (Fabrazyme)","year":"2001"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/diseases5020015","article-title":"Biomarkers and imaging findings of Anderson-Fabry disease-what we know now","volume":"5","author":"Beir\u00e3o","year":"2017","journal-title":"Diseases."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0140","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0145","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.3390\/ijms21218080","article-title":"Biomarkers in Anderson-Fabry disease","volume":"21","author":"Simonetta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0160","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/0929867324666170616102112","article-title":"Biomarkers for diagnosing and staging of Fabry disease","volume":"25","author":"Kramer","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0175","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0185","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney. Int."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0190","series-title":"Table of Surrogate Endpoints that Were the Basis of Drug Approval or Licensure","author":"US Food & Drug Administration","year":"2021"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney. Int."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0200","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney. Dis."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0205","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"Lubanda","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0210","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the international study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0215","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney. Int."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063506","article-title":"Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease","volume":"8","author":"Liebau","year":"2013","journal-title":"PLoS. One."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS. One."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168346","article-title":"Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical severity of Fabry nephropathy","volume":"11","author":"Fall","year":"2016","journal-title":"PLoS. One."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152812","article-title":"One year of enzyme replacement therapy reduces Globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease","volume":"11","author":"Najafian","year":"2016","journal-title":"PLoS. One."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0250","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0255","first-page":"807","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0260","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent Agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000479751","article-title":"Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits","volume":"138","author":"Svarstad","year":"2018","journal-title":"Nephron."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0270","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00467-018-4006-3","article-title":"Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?","volume":"33","author":"Politei","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0275","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of Globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0280","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2019.10.010","article-title":"Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis","volume":"129","author":"Rozenfeld","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0285","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0002-9149(69)90055-1","article-title":"The heart in Fabry\u2019s disease. A histochemical and electron microscopic study","volume":"24","author":"Ferrans","year":"1969","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/7b2c04df-8592-4fb7-8608-3039db28b504","article-title":"Globotriaosylsphingosine accumulation and not alpha-galactosidase-a deficiency causes endothelial dysfunction in Fabry disease","volume":"7","author":"Namdar","year":"2012","journal-title":"PLoS. One."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0300","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmg.20.4.309","article-title":"Involvement of dorsal root ganglia in Fabry\u2019s disease","volume":"20","author":"Gadoth","year":"1983","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0305","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/jnnp.36.6.1053","article-title":"Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain","volume":"36","author":"Kahn","year":"1973","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0310","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0315","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/000348948909800509","article-title":"Otologic histopathology of Fabry's disease","volume":"98","author":"Schachern","year":"1989","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166484","article-title":"Skin Globotriaosylceramide 3 load is increased in men with advanced Fabry disease","volume":"11","author":"\u00dc\u00e7eyler","year":"2016","journal-title":"PLoS. One."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0325","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2019.03.010","article-title":"Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: a 5-year randomized controlled trial","volume":"127","author":"Ramaswami","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0330","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.ejhg.5201798","article-title":"Three-dimensional face shape in Fabry disease","volume":"15","author":"Cox-Brinkman","year":"2007","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0335","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0340","first-page":"8","article-title":"Thurberg, chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases?","volume":"11","author":"Politei","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2022.10.005_bb9000","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1681\/ASN.2021010044","article-title":"Renal histologic analysis provides complementary information to kidney function measurement for patients with early diabetic or hypertensive disease","volume":"32","author":"Quinn","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0345","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0350","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.kint.2022.03.023","article-title":"A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease","volume":"102","author":"Najafian","year":"2022","journal-title":"Kidney. Int."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0355","doi-asserted-by":"crossref","first-page":"672","DOI":"10.21037\/cdt-20-981","article-title":"Fabry disease-what cardiologists can learn from the nephrologist: a narrative review","volume":"11","author":"Kurschat","year":"2021","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0360","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","article-title":"Prevalence of uncontrolled hypertension in patients with Fabry disease","volume":"19","author":"Kleinert","year":"2006","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0365","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0370","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.semnephrol.2014.06.008","article-title":"Progenitor cells and podocyte regeneration","volume":"34","author":"Shankland","year":"2014","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0375","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0380","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jgf2.76","article-title":"Fabry disease and its cardiac involvement","volume":"18","author":"Kubo","year":"2017","journal-title":"J. Gen. Fam. Med."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0385","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/qjmed\/hcy120","article-title":"Diagnosis and treatment of the cardiovascular consequences of Fabry disease","volume":"112","author":"Baig","year":"2019","journal-title":"QJM."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0395","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0400","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.clinthera.2020.10.007","article-title":"Effects of baseline left ventricular hypertrophy and decreased renal function on cardiovascular and renal outcomes in patients with Fabry disease treated with Agalsidase alfa: a Fabry outcome survey study","volume":"42","author":"Feriozzi","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0405","doi-asserted-by":"crossref","DOI":"10.1177\/2326409816661361","article-title":"The Central Nervous System Involvement in Fabry Disease:A Review","volume":"4","author":"Burlina","year":"2016","journal-title":"J. Inborn. Errors. Metab. Screen."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0410","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99171","article-title":"Neuropathic pain in a Fabry disease rat model","volume":"3","author":"Miller","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS. One."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0425","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0430","series-title":"Neurological Manifestations of Fabry Disease","author":"Schiffmann","year":"2006"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0435","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0440","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-11-61","article-title":"Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel","volume":"11","author":"Burlina","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0445","doi-asserted-by":"crossref","DOI":"10.1177\/2326409816661351","article-title":"Small Fiber neuropathy in Fabry disease: a review of pathophysiology and treatment","volume":"4","author":"Politei","year":"2016","journal-title":"J. Inborn. Errors. Metab. Screen."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0450","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10545-017-0051-5","article-title":"Hearing loss in children with Fabry disease","volume":"40","author":"Suntjens","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0455","series-title":"Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis. Copyright \u00a9 2006","article-title":"Dermatological and soft-tissue manifestations of Fabry disease: Characteristics and response to enzyme replacement therapy","author":"Lidove","year":"2006"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0460","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0465","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0470","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1096\/fj.201800771R","article-title":"\u03b1-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease","volume":"33","author":"Miller","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0475","series-title":"Dermatologic Aspects of Fabry Disease","volume":"4","author":"Luna","year":"2016"},{"key":"10.1016\/j.ymgme.2022.10.005_bb0480","first-page":"45","article-title":"Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with Agalsidase Beta: data from the Fabry registry","volume":"38","author":"Wilcox","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0485","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/j.pain.0000000000002152","article-title":"Fabry disease pain: patient and preclinical parallels","volume":"162","author":"Burand","year":"2021","journal-title":"Pain."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0490","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00006231-199809000-00009","article-title":"Gastrointestinal symptoms and delayed gastric emptying in Fabry\u2019s disease: response to metoclopramide","volume":"19","author":"Argoff","year":"1998","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0495","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1651-2227.2007.00216.x","article-title":"Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment","volume":"96","author":"Hoffmann","year":"2007","journal-title":"Acta. Paediatr."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0500","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.2174\/13816128113199990347","article-title":"Gastroenterological complications of Anderson-Fabry disease","volume":"19","author":"Buda","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0505","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/archneur.1974.00490380068009","article-title":"Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns","volume":"31","author":"Onishi","year":"1974","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0510","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF00697017","article-title":"Neuropathological and biochemical studies in Fabry\u2019s disease","volume":"30","author":"Tabira","year":"1974","journal-title":"Acta. Neuropathol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0515","first-page":"5548445","article-title":"Anderson-Fabry disease: from endothelial dysfunction to emerging therapies","volume":"2021","author":"Stamerra","year":"2021","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0520","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/ATVBAHA.113.302200","article-title":"Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in Fabry disease","volume":"34","author":"Choi","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0525","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2011.06.007","article-title":"Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide","volume":"104","author":"De Francesco","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0530","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-0004.1987.tb02820.x","article-title":"Effect of vitamin E and ticlopidine on platelet aggregation in Fabry\u2019s disease","volume":"31","author":"Sakuraba","year":"1987","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0535","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0540","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0545","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0555","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0560","article-title":"Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase a after 6 years of enzyme replacement therapy","volume":"24","author":"Hongo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0565","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","article-title":"Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis","volume":"14","author":"Ortiz","year":"2021","journal-title":"Clin. Kidney. J."},{"key":"10.1016\/j.ymgme.2022.10.005_bb0570","series-title":"Presented at 18th Annual WORLDSymposium, February 7\u201311, 2022; Virtual congress","article-title":"Overall slowing of decline in kidney function and reduction in severe clinical events in Fabry disease patients treated with agalsidase beta: a matched analysis","author":"Batista","year":"2022"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222004206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222004206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:53:07Z","timestamp":1761090787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719222004206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1096719222004206"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.10.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}